2021
DOI: 10.1186/s13063-021-05382-7
|View full text |Cite
|
Sign up to set email alerts
|

Public access to protocols of contemporary cancer randomized clinical trials

Abstract: Access to randomized clinical trial (RCT) protocols is necessary for the interpretation and reproducibility of the study results, but protocol availability has been lacking. We determined the prevalence of protocol availability for all published cancer RCTs in January 2020. We found that only 36.1% (48/133) of RCTs had an accessible protocol and only 11.3% of RCTs (15/133) had a publicly accessible protocol that was not behind a paywall. Only 18.0% (24/133) of RCTs were published in conjunction with the protoc… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
7
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 6 publications
(7 citation statements)
references
References 9 publications
(8 reference statements)
0
7
0
Order By: Relevance
“…These findings indicate that our approach of contacting authors was an ineffective method of obtaining access to protocols and SAPs. This is concerning, as many trials do not have a publicly available protocol or SAP [ 16 , 18 , 21 , 24 ], and so, for a large portion of trials, it is impossible for readers to identify whether authors have followed pre-planned methods, or whether they deviated in order to obtain more favourable results. Although authors are required to upload information about their trials to trial registry websites such as clinicaltrials.gov , the EU clinical trials register, or the ISRCTN registry, these registries provide very limited information compared to study protocols or SAPs.…”
Section: Discussionmentioning
confidence: 99%
See 2 more Smart Citations
“…These findings indicate that our approach of contacting authors was an ineffective method of obtaining access to protocols and SAPs. This is concerning, as many trials do not have a publicly available protocol or SAP [ 16 , 18 , 21 , 24 ], and so, for a large portion of trials, it is impossible for readers to identify whether authors have followed pre-planned methods, or whether they deviated in order to obtain more favourable results. Although authors are required to upload information about their trials to trial registry websites such as clinicaltrials.gov , the EU clinical trials register, or the ISRCTN registry, these registries provide very limited information compared to study protocols or SAPs.…”
Section: Discussionmentioning
confidence: 99%
“…These findings indicate that our approach of contacting authors was an ineffective method of obtaining access to protocols and SAPs. This is concerning, as many trials do not have a publicly available protocol or SAP [16,18,21,24], and so, for a large portion of trials, it is impossible for readers to identify whether authors have followed pre-planned methods, or whether they deviated in order to obtain more favourable results.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…Having a protocol that is incomplete and non-transparent makes it difficult to critically appraise the trial [ 1 ]. Protocols are needed for the readers of the corresponding paper to be able to fully appraise and interpret the results of the trial [ 2 ]. As per the 2013 SPIRIT (Standard Protocol Items: Recommendations for Interventional Trials) definition, a protocol is “a document that provides sufficient detail to enable understanding of the background, rationale, objectives, study population, interventions, methods, statistical analyses, ethical considerations, dissemination plans, and administration of the trial, replication of key aspects of trial methods and conduct; and appraisal of the trial’s scientific and ethical rigour from ethics approval to dissemination of results” (3;202).…”
Section: Background/rationalementioning
confidence: 99%
“…However, this is not always the case, and some protocol publications will require payment for access. For example, of the cancer clinical trials published in January of 2020 ( n = 113), only 11.3% had a publicly accessible protocol that was not behind a paywall [ 2 ]. This further limits transparency and hinders replication in trial methods and conduct, which has been recommended for trial retention strategies in order to improve the evidence base for their effectiveness [ 6 ].…”
Section: Background/rationalementioning
confidence: 99%